La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Catalyst Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 6/6

Catalyst Pharmaceuticals possède un total de capitaux propres de $608.7M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $706.4M et de $97.7M. L'EBIT de Catalyst Pharmaceuticals est $85.9M ce qui fait que son ratio de couverture des intérêts -10.6. Elle dispose de liquidités et de placements à court terme de $375.7M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	-10.6x
Argent liquide	US$375.69m
Fonds propres	US$608.66m
Total du passif	US$97.71m
Total des actifs	US$706.36m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition

Sep 12

Catalyst Pharma ends momentum as Roth downgrades

Aug 24

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CPRX ( $474.4M ) dépassent ses passifs à court terme ( $92.3M ).

Passif à long terme: Les actifs à court terme de CPRX ( $474.4M ) dépassent ses passifs à long terme ( $5.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: CPRX est sans dette.

Réduire la dette: CPRX n'a eu aucune dette au cours des 5 dernières années.

Couverture de la dette: CPRX n'a pas de dette, elle n'a donc pas besoin d'être couverte par le flux de trésorerie opérationnel.

Couverture des intérêts: CPRX n'a aucune dette, par conséquent la couverture des paiements d'intérêts n'est pas un problème.

Catalyst Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment deteriorates as stock falls 30%

Investor sentiment improved over the past week

Chief Medical & Regulatory Officer exercised options and sold US$100k worth of stock

Chief Accounting Officer recently sold US$2.0m worth of stock

Independent Director recently sold US$332k worth of stock

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Price target increased to US$18.10

Price target increased to US$18.10

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?